Goldhirsch A et al. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. San Antonio Breast Cancer Symposium 2012;Abstract S5-2.

Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.